July 23, 2024
  • Revenues for the first quarter increased 5.8% to $192.6 million, compared to $182.1 million in the same period in 2023.
  • Net loss was $26.5 million in the first quarter, compared to a net loss of $42.9 million in the same period last year. Adjusted EBITDA was $39.5 million, a 7.9% increase from $36.6 million in the same period last year.
  • Income from operations margin was (2.5)% in the first quarter, compared to (7.5)% in the same period last year. Adjusted EBITDA margin was 20.5% in the first quarter, compared to 20.1% in the same period last year.
  • GAAP net loss per share for the first quarter was $0.13, compared to $0.22 in the first quarter of 2023. Adjusted earnings per share for the quarter was $0.06, in-line with the same period last year.
  • The company reaffirmed full year 2024 guidance and continues to expect revenue growth of 5% to 7%, adjusted EBITDA of $193 million to $203 million, and adjusted EPS of $0.37-$0.42.

ATLANTA–(BUSINESS WIRE)–Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the first quarter ended March 31, 2024.

The first quarter was a solid start for Mirion in 2024,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Revenue growth was in-line with our expectations, led by a strong quarter from our Technologies segment. I am pleased with the Adjusted EBITDA margin expansion we delivered compared to the same period last year and believe we are well-positioned heading into the rest of 2024. Engagement remains strong across our end markets and I am particularly excited by the macro trends taking shape in nuclear power and cancer care.”

Reaffirmed 2024 Outlook

We are reaffirming our 2024 financial outlook today,” continued Mr. Logan. “I am encouraged by the commercial and operational momentum across the business and believe that we have the right strategy in place to deliver against our expectations.”

Mirion is reaffirming its guidance for the fiscal year and 12-month period ending December 31, 2024:

  • Revenue growth of 5% – 7%
    • Organic revenue growth of 4% – 6%
      • Medical +MSD organic
      • Technologies +MSD organic
    • Inorganic revenue growth of approximately 1%, primarily as a result of the ec2 acquisition
    • Minimal impact from foreign exchange rates
  • Adjusted EBITDA of $193 million – $203 million
  • Adjusted EPS of $0.37 – $0.42
  • Adjusted free cash flow of $65 million – $85 million

The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures.

Other modeling and guidance assumptions include the following:

  • Depreciation of approximately $33 million for the year
  • Net interest expense of approximately $55 million (approximately $52 million of cash interest)
  • Effective tax rate between 26% and 28%
  • Capital expenditures of approximately $40 million
  • Cash taxes of approximately $35 million
  • Approximately 204 million shares of Class A common stock outstanding (excludes 7.3 million shares of Class B common stock, 18.7 million public warrants (which were called for redemption on April 18, 2024), 8.5 million private placement warrants, 18.8 million founder shares, subject to vesting, 2.2 million restricted stock units, 1.2 million performance stock units and a further 34.3 million shares reserved for future equity awards (subject to annual automatic increases)) (all numbers as of March 31, 2024)
  • Euro to U.S. Dollar foreign exchange conversion rate of 1.08
  • Cash non-operating expenses of approximately $9 million
  • Stock-based compensation of approximately $11 million

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for organic and inorganic revenue, adjusted EBITDA, adjusted EPS and adjusted free cash flow are not available without unreasonable effort.

Conference Call

Mirion will host a conference call tomorrow, May 1, 2024 at 9:00 a.m. ET to discuss its financial results. Participants may access the call by dialing 1-844-826-3035 or 1-412-317-5195, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events.

A telephonic replay will be available shortly after the conclusion of the call and until May 15, 2024. Participants may access the replay at 1-844-512-2921, international callers may use 1-412-317-6671, and enter access code 10188006. An archived replay of the call and an accompanying presentation will also be available on the Investors section of the Mirion website at https://ir.mirion.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “should”, “would”, “will”, “understand” and similar words are intended to identify forward looking statements. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our business strategy and plans, our objectives for future operations, macroeconomic trends and macro trends in nuclear power and cancer care, foreign exchange, interest rate and inflation expectations, any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions, our future share capitalization and any exercise, exchange, redemption or other settlement of our outstanding warrants and other securities. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict in the Middle East and risks of slowing economic growth or economic recession in the United States and globally; developments in the government budgets (defense and non-defense) in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government’s failure to raise the debt ceiling; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or other security threats; risks related to the implementation and enhancement of information systems; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures and investments, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; risks associated with our limited history of operating as an independent company; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the United States Securities and Exchange Commission (the “SEC”) from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward- looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Use of Non-GAAP Financial Information

In addition to our results determined in accordance with GAAP, we believe that the presentation of non-GAAP financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the financial tables below, as well as the “Reconciliation of Non-GAAP Financial Measures” section of this press release. Non-GAAP financial information is not a substitute for GAAP financial information and undue reliance should not be placed on such non-GAAP financial information. In addition, similarly titled items used by other companies may not be comparable due to variations in how they are calculated and how terms are defined.

Channels for Disclosure of Information

Mirion intends to announce material information to the public through the Mirion Investor Relations website ir.mirion.com, SEC filings, press releases, public conference calls and public webcasts. Mirion uses these channels, as well as social media, to communicate with its investors, customers, and the public about the company, its offerings, and other issues. It is possible that the information Mirion posts on social media could be deemed to be material information. As such, Mirion encourages investors, the media, and others to follow the channels listed above, including the social media channels listed on Mirion’s investor relations website, and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Mirion will announce information will be posted on the investor relations page on Mirion’s website.

About Mirion

Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. Learn more at mirion.com.

Mirion Technologies, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In millions, except share data)

 

 

March 31, 2024

 

December 31, 2023

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

120.2

 

 

$

128.8

 

Restricted cash

 

0.4

 

 

 

0.6

 

Accounts receivable, net of allowance for doubtful accounts

 

146.1

 

 

 

172.3

 

Costs in excess of billings on uncompleted contracts

 

62.6

 

 

 

48.7

 

Inventories

 

146.8

 

 

 

144.1

 

Prepaid expenses and other current assets

 

38.5

 

 

 

44.1

 

Total current assets

 

514.6

 

 

 

538.6

 

Property, plant, and equipment, net

 

138.3

 

 

 

134.5

 

Operating lease right-of-use assets

 

31.1

 

 

 

32.8

 

Goodwill

 

1,440.2

 

 

 

1,447.6

 

Intangible assets, net

 

504.3

 

 

 

538.8

 

Restricted cash

 

1.1

 

 

 

1.1

 

Other assets

 

19.1

 

 

 

25.1

 

Total assets

$

2,648.7

 

 

$

2,718.5

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

53.1

 

 

$

58.7

 

Deferred contract revenue

 

95.8

 

 

 

103.4

 

Notes payable to third-parties, current

 

0.1

 

 

 

1.2

 

Operating lease liability, current

 

6.6

 

 

 

6.8

 

Accrued expenses and other current liabilities

 

79.0

 

 

 

95.6

 

Total current liabilities

 

234.6

 

 

 

265.7

 

Notes payable to third-parties, non-current

 

685.3

 

 

 

684.7

 

Warrant liabilities

 

61.0

 

 

 

55.3

 

Operating lease liability, non-current

 

26.5

 

 

 

28.1

 

Deferred income taxes, non-current

 

77.3

 

 

 

84.0

 

Other liabilities

 

46.1

 

 

 

50.7

 

Total liabilities

 

1,130.8

 

 

 

1,168.5

 

Commitments and contingencies (Note 10)

 

 

 

Stockholders’ equity (deficit):

 

 

 

Class A common stock; $0.0001 par value, 500,000,000 shares authorized; 218,735,333 shares issued and outstanding at March 31, 2024; 218,177,832 shares issued and outstanding at December 31, 2023

 

 

 

 

 

Class B common stock; $0.0001 par value, 100,000,000 shares authorized; 7,326,423 issued and outstanding at March 31, 2024; 7,787,333 issued and outstanding at December 31, 2023

 

 

 

 

 

Treasury stock, at cost; 149,076 shares at March 31, 2024 and December 31, 2023

 

(1.3

)

 

 

(1.3

)

Additional paid-in capital

 

2,063.9

 

 

 

2,056.5

 

Accumulated deficit

 

(531.2

)

 

 

(505.4

)

Accumulated other comprehensive loss

 

(74.2

)

 

 

(65.3

)

Mirion Technologies, Inc. stockholders’ equity

 

1,457.2

 

 

 

1,484.5

 

Noncontrolling interests

 

60.7

 

 

 

65.5

 

Total stockholders’ equity

 

1,517.9

 

 

 

1,550.0

 

Total liabilities and stockholders’ equity

$

2,648.7

 

 

$

2,718.5

 

 

Mirion Technologies, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In millions, except per share data)

 

 

Three Months

Ended March 31,

2024

 

Three Months

Ended March 31,

2023

Revenues:

 

 

 

Product

$

140.0

 

 

$

132.4

 

Service

 

52.6

 

 

 

49.7

 

Total revenues

 

192.6

 

 

 

182.1

 

Cost of revenues:

 

 

 

Product

 

79.0

 

 

 

76.8

 

Service

 

26.5

 

 

 

26.2

 

Total cost of revenues

 

105.5

 

 

 

103.0

 

Gross profit

 

87.1

 

 

 

79.1

 

Operating expenses:

 

 

 

Selling, general and administrative

 

84.1

 

 

 

85.1

 

Research and development

 

7.9

 

 

 

7.6

 

Total operating expenses

 

92.0

 

 

 

92.7

 

Loss from operations

 

(4.9

)

 

 

(13.6

)

Other expense (income):

 

 

 

Interest expense

 

15.5

 

 

 

16.0

 

Interest income

 

(1.7

)

 

 

(1.1

)

Loss on debt extinguishment

 

 

 

 

2.6

 

Foreign currency loss (gain), net

 

0.8

 

 

 

(0.3

)

Increase in fair value of warrant liabilities

 

5.7

 

 

 

13.4

 

Other expense (income), net

 

0.1

 

 

 

(0.2

)

Loss before income taxes

 

(25.3

)

 

 

(44.0

)

Loss (benefit) from income taxes

 

1.2

 

 

 

(1.1

)

Net loss

 

(26.5

)

 

 

(42.9

)

Loss attributable to noncontrolling interests

 

(0.7

)

 

 

(1.0

)

Net loss attributable to Mirion Technologies, Inc.

$

(25.8

)

 

$

(41.9

)

 

 

 

 

Net loss per common share attributable to Mirion Technologies, Inc. — basic and diluted

$

(0.13

)

 

$

(0.22

)

Weighted average common shares outstanding — basic and diluted

 

199.729

 

 

 

187.701

 

 

Mirion Technologies, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In millions)

 

 

Three Months

Ended March 31,

2024

 

Three Months

Ended March 31,

2023

OPERATING ACTIVITIES:

 

 

 

Net loss

$

(26.5

)

 

$

(42.9

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

Depreciation and amortization expense

 

38.8

 

 

 

41.3

 

Stock-based compensation expense

 

3.6

 

 

 

5.5

 

Amortization of debt issuance costs

 

0.7

 

 

 

3.5

 

Provision for doubtful accounts

 

0.8

 

 

 

0.8

 

Inventory obsolescence write down

 

1.2

 

 

 

1.0

 

Change in deferred income taxes

 

(7.5

)

 

 

(7.1

)

Loss on disposal of property, plant and equipment

 

0.3

 

 

 

0.8

 

Loss (gain) on foreign currency transactions

 

0.8

 

 

 

(0.3

)

Increase in fair values of warrant liabilities

 

5.7

 

 

 

13.4

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

24.2

 

 

 

19.1

 

Costs in excess of billings on uncompleted contracts

 

(8.2

)

 

 

(8.6

)

Inventories

 

(5.6

)

 

 

(13.9

)

Prepaid expenses and other current assets

 

4.2

 

 

 

(0.3

)

Accounts payable

 

(5.4

)

 

 

(2.5

)

Accrued expenses and other current liabilities

 

(12.3

)

 

 

(8.5

)

Deferred contract revenue and liabilities

 

(9.1

)

 

 

(3.6

)

Other assets

 

(0.2

)

 

 

0.4

 

Other liabilities

 

0.5

 

 

 

(0.8

)

Net cash provided by (used in) operating activities

 

6.0

 

 

 

(2.7

)

INVESTING ACTIVITIES:

 

 

 

Acquisitions of businesses, net of cash and cash equivalents acquired

 

(1.0

)

 

 

 

Purchases of property, plant, and equipment and badges

 

(12.8

)

 

 

(7.5

)

Proceeds from net investment hedge derivative contracts

 

0.9

 

 

 

 

Net cash used in investing activities

 

(12.9

)

 

 

(7.5

)

FINANCING ACTIVITIES:

 

 

 

Issuances of common stock

 

 

 

 

150.0

 

Common stock issuance costs

 

 

 

 

(0.2

)

Principal repayments

 

 

 

 

(125.0

)

Proceeds from net cash flow hedge derivative contracts

 

0.3

 

 

 

 

Other financing

 

(0.1

)

 

 

(0.2

)

Net cash provided by financing activities

 

0.2

 

 

 

24.6

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(2.1

)

 

 

0.7

 

Net (decrease) increase in cash, cash equivalents, and restricted cash

 

(8.8

)

 

 

15.1

 

Cash, cash equivalents, and restricted cash at beginning of period

 

130.5

 

 

 

75.0

 

Cash, cash equivalents, and restricted cash at end of period

$

121.7

 

 

$

90.1

 

 

Share Count

Consists of 199,985,333 shares of Class A common stock outstanding as of March 31, 2024. Excludes (1) 7,326,423 shares of Class B common stock outstanding as of March 31, 2024; 18,750,000 founder shares which are shares of Class A common stock subject to vesting in three equal tranches, based on the volume-weighted average price of our Class A common stock being greater than or equal to $12.00, $14.00 and $16.00 per share for any 20 trading days in any 30 consecutive trading day period, and such shares will be forfeited to us for no consideration if they fail to vest within five years after October 20, 2021; (2) 27,249,779 shares of Class A common stock issuable upon the exercise of 8,500,000 private placement warrants and 18,749,779 publicly-traded warrants, all of which publicly-traded warrants were called for redemption on April 18, 2024; (3) 2.2 million shares of Class A common stock underlying restricted stock units and 1.2 million shares of Class A common stock underlying performance stock units; and (4) any shares issuable from awards under our 2021 Omnibus Incentive Plan, which had 34,340,921 shares reserved for future equity awards (subject to annual automatic increases). The 7,326,423 shares of Class B common stock are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co., Inc. (the “paired interests”). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one basis or cash based on a trailing stock price average. All share data is of March 31, 2024 unless otherwise noted.

Reconciliation of Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Organic Revenues is defined as Revenues excluding the impact of foreign exchange rates as well as mergers, acquisitions and divestitures in the period.

Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue.

Adjusted Net Income is defined as GAAP net income adjusted for foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Contacts

For investor inquiries:
Jerry Estes

ir@mirion.com

For media inquiries:
Erin Schesny

media@mirion.com

Read full story here

The post Mirion Announces First Quarter 2024 Financial Results and Reaffirms Full Year Guidance appeared first on Daily Host News.

Mirion Announces First Quarter 2024 Financial Results and Reaffirms Full Year Guidance first appeared on Web and IT News.

Leave a Reply

Your email address will not be published. Required fields are marked *